The following is a public statement from M. Salim Siddiqui, MD, PhD, president of the Michigan State Medical Society, in response to the growing nationwide shortage of the chemotherapy drugs Cisplatin and Carboplatin.
“The escalating scarcity of two critical chemotherapy drugs, Cisplatin and Carboplatin, is reaching a tipping point with each passing day, casting a dark shadow over cancer treatment nationwide. As someone who has personally witnessed the devastating impact of cancer on families and loved ones, I cannot stress enough the urgency of this situation.
“Cisplatin and carboplatin are not only essential medications for gynecologic, breast, lung, and many other cancers, but also are used in numerous clinical trials and research studies. As confirmed by the United States Food and Drug administration (FDA), this crisis has already begun wreaking havoc on cancer centers throughout the country and is expected to last many months. Regrettably, Michigan, too, stands vulnerable to the dire consequences that will befall our cancer patients unless immediate measures are taken to enhance drug availability.
“Understanding the gravity of the situation, the Michigan State Medical Society strongly urges Michigan officials to meticulously assess regions within the state that are most susceptible to chemotherapy shortages and the subsequent impact on health care professionals and their patients. This crucial information must be expeditiously shared with the FDA Office of Drug Shortages serving as catalyst for intensified communication and collaboration with drug manufacturers. Incentives should be provided to these manufacturers encouraging them to ramp up production and alleviate the critical scarcity faced by cancer patients in Michigan.
“In addition to the urgent short-term actions, MSMS advocates for a comprehensive coordinated effort to address not only the current drug shortage but also the underlying systemic issues that contribute to such crises. It is imperative to gain a more profound understanding of the intricate drug supply chain, comprehensively evaluating every step from raw material sourcing to production quality. Manufacturers should be encouraged to demonstrate greater transparency, sharing vital information about their processes and supply sources, ultimately fostering a more robust and resilient drug supply system.
“MSMS remains committed to supporting initiatives aimed at resolving drug shortages and ensuring uninterrupted access to essential chemotherapy medications for all cancer patients. By collaborating with state and federal authorities, health care professionals, and manufacturers, we can confront this crisis, safeguarding the lives and well-being of our fellow Michiganders.”